Genetic instability in human embryonic stem cells: Prospects and caveats

Future Oncology

Volumn 9, Issue 6, 2013, Pages 867-877

  Nouspikel, Thierry ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

cancer; cell cycle checkpoints; DNA repair; genomic instability; human embryonic stem cells; mutagenesis

Indexed keywords

PROTEIN BCL 6; PROTEIN P21; PROTEIN P53;

APOPTOSIS; CELL ACTIVITY; CELL CYCLE REGULATION; CELL DIFFERENTIATION; CELL MUTANT; CELL POPULATION; CELL PROLIFERATION; CHROMOSOME ABERRATION; DNA DAMAGE; DNA REPAIR; EMBRYONAL CARCINOMA; EMBRYONIC STEM CELL; EXCISION REPAIR; G1 PHASE CELL CYCLE CHECKPOINT; GENE MUTATION; GENOMIC INSTABILITY; HUMAN; INDUCED MUTATION; MUTATION RATE; PRIORITY JOURNAL; REVIEW; STEM CELL TRANSPLANTATION;

APOPTOSIS; CELL TRANSFORMATION, NEOPLASTIC; CHROMOSOME ABERRATIONS; DNA DAMAGE; DNA REPAIR; EMBRYONIC STEM CELLS; GENOME, HUMAN; GENOMIC INSTABILITY; HUMANS; MUTATION; TISSUE THERAPY;

EID: 84878495156     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.13.22     Document Type: Review

References (86)

1. Van Hoof D, D'Amour KA, German MS. Derivation of insulin-producing cells from human embryonic stem cells. Stem Cell Res. 3(2-3), 73-87 (2009).
2. Loewenbruck K, Storch A. Stem cell-based therapies in Parkinson's disease: future hope or current treatment option? J. Neurol. 258(Suppl. 2), S346-S353 (2011).
3. Wong SS, Bernstein HS. Cardiac regeneration using human embryonic stem cells: producing cells for future therapy. Regen. Med. 5(5), 763-775 (2010).
4. Menendez P, Bueno C, Wang L, Bhatia M. Human embryonic stem cells: potential tool for achieving immunotolerance? Stem Cell Rev. 1(2), 151-158 (2005).
5. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fbroblast cultures by defned factors. Cell 126(4), 663-676 (2006).
6. Blum B, Benvenisty N. The tumorigenicity of diploid and aneuploid human pluripotent stem cells. Cell Cycle 8(23), 3822-3830 (2009).
7. Goldring CE, Duffy PA, Benvenisty N et al. Assessing the safety of stem cell therapeutics. Cell Stem Cell 8(6), 618-628 (2011)
8. Tichy ED. Mechanisms maintaining genomic integrity in embryonic stem cells and induced pluripotent stem cells. Exp. Biol. Med. (Maywood) 236(9), 987-996 (2011).
9. Ben-David U, Benvenisty N. The tumorigenicity of human embryonic and induced pluripotent stem cells. Nat. Rev. Cancer 11(4), 268-277 (2011).
10. Harrison NJ, Baker D, Andrews PW. Culture adaptation of embryonic stem cells echoes germ cell malignancy. Int. J. Androl. 30(4), 275-281; discussion 281 (2007).
11. Baker DE, Harrison NJ, Maltby E et al. Adaptation to culture of human embryonic stem cells and oncogenesis in vivo. Nat. Biotechnol. 25(2), 207-215 (2007).
12. Narva E, Autio R, Rahkonen N et al. High-resolution DNA analysis of human embryonic stem cell lines reveals culture-induced copy number changes and loss of heterozygosity. Nat. Biotechnol. 28(4), 371-377 (2010).
13. Laurent LC, Ulitsky I, Slavin I et al. Dynamic changes in the copy number of pluripotency and cell proliferation genes in human ESCs and iPSCs during reprogramming and time in culture. Cell Stem Cell 8(1), 106-118 (2011).
14. Draper JS, Smith K, Gokhale P et al. Recurrent gain of chromosomes 17q and 12 in cultured human embryonic stem cells. Nat. Biotechnol. 22(1), 53-54 (2004).
15. Funk WD, Labat I, Sampathkumar J et al. Evaluating the genomic and sequence integrity of human ES cell lines; comparison to normal genomes. Stem Cell Res. 8(2), 154-164 (2012).
16. Werbowetski-Ogilvie TE, Bosse M, Stewart M et al. Characterization of human embryonic stem cells with features of neoplastic progression. Nat. Biotechnol. 27(1), 91-97 (2009).
17. Solter D. From teratocarcinomas to embryonic stem cells and beyond: a history of embryonic stem cell research. Nat. Rev. Genet. 7(4), 319-327 (2006).
18. Andrews PW. From teratocarcinomas to embryonic stem cells. Philos. Trans. R. Soc. Lond. B Biol. Sci. 357(1420), 405-417 (2002).
19. Hyka-Nouspikel N, Lemonidis K, Lu WT, Nouspikel T. Circulating human B lymphocytes are defcient in nucleotide excision repair and accumulate mutations upon proliferation. Blood 117(23), 6277-6286 (2011).
20. Hyka-Nouspikel N, Desmarais J, Gokhale PJ et al. Defcient DNA damage response and cell cycle checkpoints lead to accumulation of point mutations in human embryonic stem cells. Stem Cells 30(9), 1901-1910 (2012).
21. Gillet LC, Scharer OD. Molecular mechanisms of mammalian global genome nucleotide excision repair. Chem. Rev. 106(2), 253-276 (2006).
22. Wood RD. DNA damage recognition during nucleotide excision repair in mammalian cells. Biochimie 81(1-2), 39-44 (1999).
23. Nouspikel T. DNA Repair in mammalian cells: nucleotide excision repair: variations on versatility. Cell. Mol. Life Sci. 66(6), 994-1009 (2009).
24. Tornaletti S. DNA repair in mammalian cells: transcription-coupled DNA repair: directing your effort where it's most needed. Cell. Mol. Life Sci. 66 (6), 1010-1020 (2009).
25. Kraemer KH, Lee MM, Scotto J. DNA repair protects against cutaneous and internal neoplasia: evidence from xeroderma pigmentosum. Carcinogenesis 5 (4), 511-514 (1984).
26. Nouspikel T. DNA repair in differentiated cells: some new answers to old questions. Neuroscience 145, 1213-1221 (2007).
27. Nouspikel T, Hanawalt PC. Terminally differentiated human neurons repair transcribed genes but display attenuated global DNA repair and modulation of repair gene expression. Mol. Cell Biol. 20, 1562-1570 (2000).
28. Nouspikel T, Hanawalt PC. Impaired nucleotide excision repair upon macrophage differentiation is corrected by E1 ubiquitin-activating enzyme. Proc. Natl Acad. Sci. USA 103 (44), 16188-16193 (2006).
29. Hsu PS, Hanawalt PC, Nouspikel T. Nucleotide excision repair phenotype of human acute myeloid leukemia cell lines at various stages of differentiation. Mutat. Res. 614 (1-2), 3-15 (2007).
30. Nouspikel TP, Hyka-Nouspikel N, Hanawalt PC. Transcription domain-associated repair in human cells. Mol. Cell Biol. 26(23), 8722-8730 (2006).
31. Nouspikel T, Hanawalt PC. DNA repair in terminally differentiated cells. DNA Repair 1, 59-75 (2002).
32. Park IH, Zhao R, West JA et al. Reprogramming of human somatic cells to pluripotency with defned factors. Nature 451(7175), 141-146 (2008).
33. Momcilovic O, Knobloch L, Fornsaglio J, Varum S, Easley C, Schatten G. DNA damage responses in human induced pluripotent stem cells and embryonic stem cells. PLoS One 5 (10), e13410 (2010).
34. Maherali N, Ahfeldt T, Rigamonti A, Utikal J, Cowan C, Hochedlinger K. A high-effciency system for the generation and study of human induced pluripotent stem cells. Cell Stem Cell 3(3), 340-345 (2008).
35. Avery K, Avery S, Shepherd J, Heath PR, Moore H. Sphingosine-1-phosphate mediates transcriptional regulation of key targets associated with survival, proliferation, and pluripotency in human embryonic stem cells. Stem Cells Dev. 17(6), 1195-1205 (2008).
36. Lu SJ, Hipp JA, Feng Q, Hipp JD, Lanza R, Atala A. GeneChip analysis of human embryonic stem cell differentiation into hemangioblasts: an in silico dissection of mixed phenotypes. Genome Biol. 8(11), R240 (2007).
37. Maynard S, Swistowska AM, Lee JW et al. Human embryonic stem cells have enhanced repair of multiple forms of DNA damage. Stem Cells 26(9), 2266-2274 (2008).
38. Van Sloun PP, Jansen JG, Weeda G et al. The role of nucleotide excision repair in protecting embryonic stem cells from genotoxic effects of UV-induced DNA damage. Nucleic Acids Res. 27(16), 3276-3282 (1999).
39. Sancar A, Lindsey-Boltz LA, Unsal-Kacmaz K, Linn S. Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Ann. Rev. Biochem. 73, 39-85 (2004).
40. Barta T, Vinarsky V, Holubcova Z et al. Human embryonic stem cells are capable of executing G1/S checkpoint activation. Stem Cells 28(7), 1143-1152 (2010).
41. Lee J, Go Y, Kang I, Han YM, Kim J. Oct-4 controls cell-cycle progression of embryonic stem cells. Biochem. J. 426(2), 171-181 (2010).
42. Momcilovic O, Choi S, Varum S, Bakkenist C, Schatten G, Navara C. Ionizing radiation induces ataxia telangiectasia mutated-dependent checkpoint signaling and G (2) but not G(1) cell cycle arrest in pluripotent human embryonic stem cells. Stem Cells 27(8), 1822-1835 (2009).
43. Mazroui R, Di Marco S, Kaufman RJ, Gallouzi IE. Inhibition of the ubiquitin-proteasome system induces stress granule formation. Mol. Biol. Cell 18(7), 2603-2618 (2007).
44. Iakova P, Wang GL, Timchenko L et al. Competition of CUGBP1 and calreticulin for the regulation of p21 translation determines cell fate. EMBO J. 23(2), 406-417 (2004).
45. Wang Y, Baskerville S, Shenoy A, Babiarz JE, Baehner L, Blelloch R. Embryonic stem cell-specifc microRNAs regulate the G1-S transition and promote rapid proliferation. Nat. Genet. 40(12), 1478-1483 (2008).
46. Malashicheva AB, Kislyakova TV, Aksenov ND, Osipov KA, Pospelov VA. F9 embryonal carcinoma cells fail to stop at G1/S boundary of the cell cycle after gamma-irradiation due to p21WAF1/CIP1 degradation. Oncogene 19(34), 3858-3865 (2000).
47. Lehmann AR, Niimi A, Ogi T et al. Translesion synthesis: Y-family polymerases and the polymerase switch. DNA Repair (Amst.) 6(7), 891-899 (2007).
48. Ulrich HD. Timing and spacing of ubiquitin-dependent DNA damage bypass. FEBS Lett. 585(18), 2861-2867 (2011).
49. Branzei D. Ubiquitin family modifcations and template switching. FEBS Lett. 585(18), 2810-2817 (2011).
50. McCulloch SD, Kunkel TA. The fdelity of DNA synthesis by eukaryotic replicative and translesion synthesis polymerases. Cell Res. 18(1), 148-161 (2008).
51. Luo LZ, Gopalakrishna-Pillai S, Nay SL et al. DNA repair in human pluripotent stem cells is distinct from that in non-pluripotent human cells. PLoS One 7(3), e30541 (2012).
52. Fung H, Weinstock DM. Repair at single targeted DNA double-strand breaks in pluripotent and differentiated human cells. PLoS One 6(5), e20514 (2011).
53. Adams BR, Golding SE, Rao RR, Valerie K. Dynamic dependence on ATR and ATM for double-strand break repair in human embryonic stem cells and neural descendants. PLoS One 5(4), e10001 (2010).
54. Fan J, Robert C, Jang YY et al. Human induced pluripotent cells resemble embryonic stem cells demonstrating enhanced levels of DNA repair and effcacy of nonhomologous end-joining. Mutat. Res. 713(1-2), 8-17 (2011).
55. Garcia-Fernandez M, Kissel H, Brown S et al. Sept4/ARTS is required for stem cell apoptosis and tumor suppression. Genes Dev. 24(20), 2282-2293 (2010).
56. Shaffer AL, Yu X, He Y, Boldrick J, Chan EP, Staudt LM. BCL-6 represses genes that function in lymphocyte differentiation, infammation, and cell cycle control. Immunity 13(2), 199-212 (2000).
57. Capello D, Vitolo U, Pasqualucci L et al. Distribution and pattern of BCL-6 mutations throughout the spectrum of B-cell neoplasia. Blood 95(2), 651-659 (2000).
58. Migliazza A, Martinotti S, Chen W et al. Frequent somatic hypermutation of the 5́ noncoding region of the BCL6 gene in B-cell lymphoma. Proc. Natl Acad. Sci. USA 92(26), 12520-12524 (1995).
59. Hong Y, Cervantes RB, Tichy E, Tischfeld JA, Stambrook PJ. Protecting genomic integrity in somatic cells and embryonic stem cells. Mutat. Res. 614(1-2), 48-55 (2007).
60. Cervantes RB, Stringer JR, Shao C, Tischfeld JA, Stambrook PJ. Embryonic stem cells and somatic cells differ in mutation frequency and type. Proc. Natl Acad. Sci. USA 99(6), 3586-3590 (2002).
61. Larson JS, Yin M, Fischer JM, Stringer SL, Stringer JR. Expression and loss of alleles in cultured mouse embryonic fbroblasts and stem cells carrying allelic fuorescent protein genes. BMC Mol. Biol. 7, 36 (2006).
62. Chen Y, Yee D, Dains K et al. Genotype-based screen for ENU-induced mutations in mouse embryonic stem cells. Nat. Genet. 24 (3), 314-317 (2000).
63. Denissova NG, Tereshchenko I V, Cui E, Stambrook PJ, Shao C, Tischfeld JA. Ionizing radiation is a potent inducer of mitotic recombination in mouse embryonic stem cells. Mutat. Res. 715(1-2), 1-6 (2011).
64. Corbet SW, Clarke AR, Gledhill S, Wyllie AH. P53-dependent and-independent links between DNA-damage, apoptosis and mutation frequency in ES cells. Oncogene 18 (8), 1537-1544 (1999).
65. Donahue SL, Lin Q, Cao S, Ruley HE. Carcinogens induce genome-wide loss of heterozygosity in normal stem cells without persistent chromosomal instability. Proc. Natl Acad. Sci. USA 103(31), 11642-11646 (2006).
66. Hendriks G, Calleja F, Vrieling H, Mullenders LH, Jansen JG, de Wind N. Gene transcription increases DNA damage-induced mutagenesis in mammalian stem cells. DNA Repair (Amst.) 7(8), 1330-1339 (2008).
67. Munroe RJ, Bergstrom RA, Zheng QY et al. Mouse mutants from chemically mutagenized embryonic stem cells. Nat. Genet. 24(3), 318-321 (2000).
68. Bogomazova AN, Lagarkova MA, Tskhovrebova LV, Shutova M V, Kiselev SL. Error-prone nonhomologous end joining repair operates in human pluripotent stem cells during late G2. Aging (Albany NY) 3(6), 584-596 (2011).
69. Gore A, Li Z, Fung HL et al. Somatic coding mutations in human induced pluripotent stem cells. Nature 471(7336), 63-67 (2011).
70. Lapidot T, Sirard C, Vormoor J et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367(6464), 645-648 (1994).
71. Collins AT, Habib FK, Maitland NJ, Neal DE. Identifcation and isolation of human prostate epithelial stem cells based on alpha(2)beta(1)-integrin expression. J. Cell Sci. 114(Pt 21), 3865-3872 (2001).
72. Singh SK, Clarke ID, Terasaki M et al. Identifcation of a cancer stem cell in human brain tumors. Cancer Res. 63(18), 5821-5828 (2003).
73. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identifcation of tumorigenic breast cancer cells. Proc. Natl Acad. Sci. USA 100 (7), 3983-3988 (2003).
74. O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumor growth in immunodefcient mice. Nature 445(7123), 106-110 (2007).
75. Ricci-Vitiani L, Lombardi DG, Pilozzi E et al. Identifcation and expansion of human colon-cancer-initiating cells. Nature 445 (7123), 111-115 (2007).
76. Li F, Tiede B, Massague J, Kang Y. Beyond tumorigenesis: cancer stem cells in metastasis. Cell Res. 17(1), 3-14 (2007).
77. Jordan C T. Cancer stem cells: controversial or just misunderstood? Cell Stem Cell 4(3), 203-205 (2009).
78. Maitland NJ, Collins AT. Prostate cancer stem cells: a new target for therapy. J. Clin. Oncol. 26(17), 2862-2870 (2008).
79. Sell S. Potential gene therapy strategies for cancer stem cells. Curr. Gene Ther. 6(5), 579-591 (2006).
80. Clarke MF, Dick JE, Dirks PB et al. Cancer stem cells-perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res. 66(19), 9339-9344 (2006).
81. Jagani Z, Khosravi-Far R. Cancer stem cells and impaired apoptosis. Adv. Exp. Med. Biol. 615, 331-344 (2008).
82. Widschwendter M, Fiegl H, Egle D et al. Epigenetic stem cell signature in cancer. Nat. Genet. 39(2), 157-158 (2007).
83. Eastham AM, Spencer H, Soncin F et al. Epithelial-mesenchymal transition events during human embryonic stem cell differentiation. Cancer Res. 67(23), 11254-11262 (2007).
84. Gerson SL, Reese J, Kenyon J. DNA repair in stem cell maintenance and conversion to cancer stem cells. Ernst Schering Found Symp. Proc. (5), 231-244 (2006).
85. Parry JM, Shamsher M, Skibinski DO. Restriction site mutation ana lysis, a proposed methodology for the detection and study of DNA base changes following mutagen exposure. Mutagenesis 5(3), 209-212 (1990).
86. Bielas JH, Loeb LA. Quantifcation of random genomic mutations. Nat. Methods 2(4), 285-290 (2005).